Fresh analysis indicates that patients who discontinue blockbuster slimming jabs like Mounjaro or Wegovy may regain lost weight at a significantly accelerated pace than those who stop traditional lifestyle programs.
Findings released in a prominent medical journal shows that while overweight people often shed about a fifth of their total mass while undergoing treatment, the mass returns at an average rate of 0.8 kg per month after stopping.
"People using these medications must be aware of the potential of quick weight regain when the treatment ends," stated researcher Dr. Susan Jebb.
Such speed of regain suggests a reversion to pre-treatment weight within about a year and a half.
Comparing Approaches
The research, which examined 37 of trials involving over 9,000 of patients, compared the effects of these new drugs with other pills.
The team emphasize that people who shed pounds through diet and exercise generally have a slower weight regain—approximately 100 grams monthly—post-intervention.
The Reason for the Fast Rebound
Doctors believe the mode of action of the drugs accounts for the accelerated rebound.
The injections copy a natural hormone called GLP-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 concentrations far above than the body's typical production might result in the system to generate a reduced amount of its own natural hormone, and could reduce sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this GLP-1 'fix' means appetite is uncontrolled, making overeating far more likely."
A Chronic Issue?
Health authorities recommend the injections for people with obesity-related medical conditions, alongside prescribed lifestyle changes.
Many experts say that, due to the likelihood of weight regain, the therapy might need to be life-long.
This view is reinforced by pharmaceutical companies, who state that the results "emphasize the long-term nature of excess weight," comparing it to managing conditions like diabetes.
User Experiences
People who have stopped the jabs describe a sudden return of cravings.
"I experienced a trigger that goes on and I was suddenly starving," said a patient.
This difficulty is worsened if individuals have not established permanent dietary or behavioural changes during therapy.
Significant Interest
Survey data show that a significant number of adults in the UK have used these injections in the last 12 months, with interest remaining high.
- Use is higher among women than males.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, researchers emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a permanent fix and long-term success hinges on integrated behavioural management.